Lessons Learned from Use of Highly Active Antiretroviral Therapy in Africa
Open Access
- 1 August 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (3), 376-385
- https://doi.org/10.1086/431482
Abstract
Background. Because antiretrovirals are becoming increasingly available in developing countries, we reviewed the findings of studies that have documented highly active antiretroviral therapy (HAART) use in Africa to identify lessons learned. With the World Health Organization (WHO) guidelines used as a frame of reference, we assessed the feasibility of implementing such programs in Africa. Moreover, clinical and laboratory outcomes were compiled to determine the effectiveness of HAART programs. Methods. We searched academic databases and recent conference abstracts for studies, and we included all studies that documented patients receiving HAART in Africa. In particular, we examined studies for such program features as type of regimen and frequency of monitoring, in addition to evaluations of patient outcomes. Results. Twenty-eight articles and abstracts involving studies from 14 African countries were reviewed. Overall, 6052 patients (96.4%) were receiving HAART, mainly consisting of 2 nucleoside reverse-transcriptase inhibitors (NRTIs) and 1 nonnucleoside reverse-transcriptase inhibitor. All studies reported an increase in mean and median CD4 cell counts, and a median of 73% of patients achieved undetectable viral loads by the end of the study period. Monitoring of CD4 cell count and viral load at 6-month intervals was completed by all studies. The median weight gained was 5.0 kg, and the median mortality rate was 7.4% (range, 0%–27%). Six studies reported that 68%–99% of patients took >95% of medications. Five studies measured drug resistance; most cases of resistance involved NRTIs. Conclusions. Many studies reported positive health outcomes, including high levels of treatment adherence that were comparable to those of industrialized countries. Regimens and monitoring means based on WHO guidelines were implemented—and at times, exceeded—in all studies reviewed. We found compelling evidence that HAART can be feasibly administered in resource-limited settings.Keywords
This publication has 16 references indexed in Scilit:
- The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical modelsAIDS, 2005
- Long-Term Benefits of Highly Active Antiretroviral Therapy in Senegalese HIV-1-Infected AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- A Pilot Study of Once-Daily Antiretroviral Therapy Integrated With Tuberculosis Directly Observed Therapy in a Resource-Limited SettingJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trialThe Lancet, 2004
- Changes in Total Lymphocyte Count as a Surrogate for Changes in CD4 Count Following Initiation of HAART: Implications for Monitoring in Resource-Limited SettingsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South AfricaAIDS, 2004
- Doubts about DOT: antiretroviral therapy for resource-poor countriesAIDS, 2003
- Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in SenegalAIDS, 2003
- Antiretroviral therapy in the private sector of Nairobi, KenyaAIDS, 2003
- Preventing antiretroviral anarchy in sub-Saharan AfricaThe Lancet, 2001